Article
Oncology
Stefan Knop, Maria-Victoria Mateos, Meletios A. Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ganna Usenko, Ludek Pour, Mark Cook, Sebastian Grosicki, Andre Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Losava, Tomoaki Fujisaki, Mamta Garg, Jianping Wang, Susan Wroblewski, Anupa Kudva, Katharine S. Gries, John Fastenau, Jesus San-Miguel, Michele Cavo
Summary: In the ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved health-related quality of life in transplant-ineligible patients with NDMM, showing enhancements in functioning and symptoms.
Article
Oncology
Pieter Sonneveld, Meletios A. Dimopoulos, Meral Beksac, Bronno van der Holt, Sara Aquino, Heinz Ludwig, Sonja Zweegman, Thilo Zander, Elena Zamagni, Ruth Wester, Roman Hajek, Lucia Pantani, Luca Dozza, Francesca Gay, AnneMaria Cafro, Luca De Rosa, Annamaria Morelli, Henrik Gregersen, Nina Gulbrandsen, Petra Cornelisse, Rosella Troia, Stefania Oliva, Vincent van de Velden, KaLung Wu, Paula F. Ypma, Gerard Bos, Mark-David Levin, Luca Pour, Christoph Driessen, Annemiek Broijl, Alexandra Croockewit, Monique C. Minnema, Anders Waage, Cecilie Hveding, Niels W. C. J. van de Donk, Massimo Offidani, Giuseppe A. Palumbo, Andrew Spencer, Mario Boccadoro, Michele Cavo
Summary: Consolidation treatment with VRD followed by lenalidomide maintenance improves PFS and depth of response in newly diagnosed patients with multiple myeloma compared to maintenance alone.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Radowan A. Elnair, Sarah A. Holstein
Summary: Multiple myeloma (MM) is considered incurable, but advancements in treatment options over the past 20 years have led to improved response rates and survival rates. Induction regimens have evolved from alkylator-based therapies to those consisting of immunomodulatory drugs and proteasome inhibitors. Standard regimens have emerged for both transplant-eligible and transplant-ineligible patient populations.
Article
Hematology
Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Philip Twumasi-Ankrah, Godwin Yung, Robert M. Rifkin, Philippe Moreau, Sagar Lonial, Shaji K. Kumar, Paul G. Richardson, S. Vincent Rajkumar
Summary: Continuous treatment with lenalidomide-dexamethasone (Rd) plus ixazomib showed a progression-free survival benefit compared to placebo in transplant-ineligible newly diagnosed multiple myeloma patients. Addition of ixazomib to Rd led to higher rates of complete and very good partial response, especially in high-risk cytogenetics subgroup. The combination therapy was generally well-tolerated with manageable toxicities and no new safety signals observed.
Article
Oncology
Aurore Perrot, Thierry Facon, Torben Plesner, Saad Z. Usmani, Shaji Kumar, Nizar J. Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Jianming He, Kai Fai Ho, Rian Van Rampelbergh, Clarissa M. Uhlar, Jianping Wang, Rachel Kobos, Katharine S. Gries, John Fastenau, Katja Weisel
Summary: The study found that D-Rd compared to Rd was associated with faster and sustained clinically meaningful improvements in patient-reported outcomes, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhaka, Susan Bal, Smith Gid, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Had, Natalie S. Callander
Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Shaji K. Kumar
Summary: The treatment of multiple myeloma has advanced in the past decade, but it remains a chronic disease. Customized treatment approaches are needed for different patients. Combination drug regimens can deepen disease response, and further research is required on treatment options post-autologous stem cell transplant.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Hematology
Jesus San-Miguel, Herve Avet-Loiseau, Bruno Paiva, Shaji Kumar, Meletios A. Dimopoulos, Thierry Facon, Maria-Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis
Summary: In patients with transplant-ineligible newly diagnosed multiple myeloma, daratumumab-based therapy reduces the risk of disease progression or death. MRD-negative status and sustained MRD negativity are associated with improved progression-free survival, and daratumumab-based therapy improves rates of MRD negativity lasting 6 or 12 months.
Article
Oncology
Chuanying Geng, Huixing Zhou, Huijuan Wang, Yanchen Li, Yun Leng, Zhiyao Zhang, Yuan Jian, Guangzhong Yang, Wenming Chen
Summary: This study found that ASCT may improve the overall survival (OS) and progression-free survival (PFS) of CD56 positive patients, while not impacting the survival of CD56 negative patients.
Article
Oncology
Rafael Fonseca, Thierry Facon, Mahmoud Hashim, Sandhya Nair, Jianming He, Eric Ammann, Annette Lam, Mark Wildgust, Shaji Kumar
Summary: This study used a clinical simulation to assess the outcomes of different treatment sequences in patients with newly diagnosed multiple myeloma (NDMM). The results support the use of daratumumab, lenalidomide, and dexamethasone (D-Rd) as initial therapy, rather than delaying the use of daratumumab.
Article
Hematology
Graham H. Jackson, Charlotte Pawlyn, David A. Cairns, Alina Striha, Corinne Collett, Anna Waterhouse, John R. Jones, Jamie Wilson, Craig Taylor, Bhuvan Kishore, Mamta Garg, Cathy D. Williams, Kamaraj Karunanithi, Jindriska Lindsay, Matthew W. Jenner, Gordon Cook, Nigel H. Russell, Mark T. Drayson, Martin F. Kaiser, Roger G. Owen, Walter M. Gregory, Faith E. Davies, Gareth J. Morgan
Summary: The Myeloma XI study compared the efficacy of thalidomide and lenalidomide in treating newly diagnosed transplant-ineligible myeloma patients, finding that CRDa had deeper responses for patients aged <= 70 years, but limited tolerability in older, frailer patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Clinical Neurology
Jinghua Liu, Jing Shen, Daihong Liu
Summary: The current report describes 3 cases of newly diagnosed multiple myeloma (MM) patients with central nervous system involvement (CNS-MM), all presenting with skull-derived plasmacytomas. One case had disease progression and died within 9 months, while the other two cases survived for over 3 years after receiving chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). The use of a modified conditioning regimen for auto-HSCT improved the prognosis of CNS-MM.
FRONTIERS IN NEUROLOGY
(2023)
Article
Oncology
Niels W. C. J. van de Donk
Summary: The evaluation of circulating plasma cells in newly diagnosed multiple myeloma patients is essential to differentiate between MM and pPCL. A new study challenges the current threshold of >= 5% circulating plasma cells and suggests that a threshold of 2% circulating tumor cells may identify a subset of ultra-high-risk MM patients with comparable prognosis as pPCL. This finding has implications for treatment decisions and clinical trial enrollment.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Yawen Wang, Jiadai Xu, Bei Xu, Panpan Li, Yang Yang, Wenjing Wang, Tianhong Xu, Aziguli Maihemaiti, Tianwei Lan, Pu Wang, Liang Ren, Chi Zhou, Xianmuseye Aihemaiti, Peng Liu
Summary: This study analyzed the data of 1068 newly diagnosed multiple myeloma patients from China. It was found that 51.9% of patients had 1q gain/amplification, which was associated with aggressive clinical characteristics and inferior survival. Upfront autologous stem cell transplantation could eliminate the adverse prognostic effect of 1q gain. However, patients with 1q gain achieved very good partial response rapidly but had inferior survival. A new risk stratification model was constructed and showed better predictive ability than existing models.
Article
Oncology
Thierry Facon, Gordon Cook, Saad Z. Usmani, Cyrille Hulin, Shaji Kumar, Torben Plesner, Cyrille Touzeau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Hartmut Goldschmidt, Hang Quach, Mohamad Mohty, Christopher P. Venner, Katja Weisel, Noopur Raje, Benjamin Hebraud, Karim Belhadj-Merzoug, Lotfi Benboubker, Olivier Decaux, Salomon Manier, Denis Caillot, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, Sonja Zweegman
Summary: In patients with transplant-ineligible newly diagnosed multiple myeloma, the combination of daratumumab plus lenalidomide/dexamethasone improved progression-free survival compared to lenalidomide/dexamethasone alone. This benefit was observed regardless of patients' frailty status. Daratumumab showed improved response rates and minimal residual disease negativity across subgroups.